Under one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it publishes its inaugural recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for broader and more equitable access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key obstacles to universal access to the jabs that can help people shift substantial weight, notes the organization.
GLP-1 Therapy Scarcity
Even in the current most optimistic outlook, the production of these medications could only cover around 100 million people – under 10% of those who need them, per the health organization.
The advice urges nations and manufacturers to expand access, via approaches such as licensing agreements.
A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
How Obesity Jabs Operate
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so users reduce food intake.
Individuals usually see weight reduction within a few weeks of commencing the regular doses.
Research points to patients may regain a significant portion after a year of halting the treatment, because their normal food cravings come back.
To be above a healthy weight increases your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity impacts individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
